Search Results - "amyloid"
Suggested Topics within your search.
Suggested Topics within your search.
- physiopathology
- Alzheimer Disease 15
- Alzheimer's disease 9
- Pathophysiology 9
- Amyloid beta-Peptides 6
- Amyloid beta-protein 6
- Chemotherapy 6
- Dementia 6
- Diagnostic Imaging 6
- Treatment 6
- drug therapy 6
- toxicity 6
- Age factors 3
- Age of Onset 3
- Aging 3
- Amyloid 3
- Amyloid Aging 3
- Amyloid beta-Protein Precursor 3
- Australia 3
- Biomarkers 3
- Degeneration 3
- Epistasis, Genetic 3
- Genetic Heterogeneity 3
- Genetic Predisposition to Disease 3
- Genetic Testing 3
- Genetic aspects 3
- HSP40 Heat-Shock Proteins 3
- Longditudinal Studies 3
- Molecular chaperones 3
- Nervous system 3
-
1
Imaging amyloid now that we can see it, what does it all mean? /
Published 2010Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series
Electronic Video -
2
Imaging amyloid now that we can see it, what does it all mean? /
Published 2010Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series
Electronic Video -
3
Imaging amyloid now that we can see it, what does it all mean? /
Published 2010Table of Contents: “…Contents: Amyloid imaging PET tracers -- Development and validation -- Amyloid imaging in dementia -- Amyloid imaging in mild cognitive impairment -- Amyloid imaging in cognitively normal elderly -- Consequences of being amyloid-positive.…”
Get full text
Series
Electronic Video -
4
Abeta toxicity Part 2 /
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
5
Abeta toxicity Part 1 /
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
6
Abeta toxicity 2
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
7
Abeta toxicity 2
Published 2011Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
8
Abeta toxicity 1
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
9
Abeta toxicity 1
Published 2011Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)
Electronic Video -
10
Genetics of early onset Alzheimer's disease
Published 2014Table of Contents: “…Contents: Role of amyloid precursor protein (APP) in Alzheimer's Disease (AD) -- Presenilins as AD causing genes -- Phenotypic heterogeneity in cases with presenilin mutations -- Gene-gene interactions in patients with AD -- Genetic testing in AD.…”
Get full text
Series
Electronic Video -
11
Genetics of early onset Alzheimer's disease
Published 2014Table of Contents: “…Contents: Role of amyloid precursor protein (APP) in Alzheimer's Disease (AD) -- Presenilins as AD causing genes -- Phenotypic heterogeneity in cases with presenilin mutations -- Gene-gene interactions in patients with AD -- Genetic testing in AD.…”
Get full text
Series
Electronic Video -
12
Genetics of early onset Alzheimer's disease
Published 2014Table of Contents: “…Contents: Role of amyloid precursor protein (APP) in Alzheimer's Disease (AD) -- Presenilins as AD causing genes -- Phenotypic heterogeneity in cases with presenilin mutations -- Gene-gene interactions in patients with AD -- Genetic testing in AD.…”
Get full text
Series
Electronic Video -
13
Roles for Hsp40 molecular chaperones in protein misfolding disease
Published 2012Table of Contents: “…Contents: Protein aggregation in conformational disease -- The Hsp40 system -- The Hsp70 system -- Small oligomers, prion, yeast, Huntington's disease and protein triage -- Mechanisms for proteotoxicity -- Mechanisms for amyloid disease.…”
Get full text
Series
Electronic Video -
14
Roles for Hsp40 molecular chaperones in protein misfolding disease
Published 2012Table of Contents: “…Contents: Protein aggregation in conformational disease -- The Hsp40 system -- The Hsp70 system -- Small oligomers, prion, yeast, Huntington's disease and protein triage -- Mechanisms for proteotoxicity -- Mechanisms for amyloid disease.…”
Get full text
Series
Electronic Video -
15
Roles for Hsp40 molecular chaperones in protein misfolding disease
Published 2012Table of Contents: “…Contents: Protein aggregation in conformational disease -- The Hsp40 system -- The Hsp70 system -- Small oligomers, prion, yeast, Huntington's disease and protein triage -- Mechanisms for proteotoxicity -- Mechanisms for amyloid disease.…”
Get full text
Series
Electronic Video -
16
Neuroimaging markers in AD trials
Published 2010Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series
Electronic Video -
17
Neuroimaging markers in AD trials
Published 2010Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series
Electronic Video -
18
Neuroimaging markers in AD trials
Published 2010Table of Contents: “…Contents: Imaging in Alzheimer's Disease (AD) trials -- Increasing range of modalities to measure brain structure, function and molecular pathology of AD -- Early diagnosis, inclusion markers and measurement of progression -- MRI to measure atrophy -- PET to measure amyloid.…”
Get full text
Series
Electronic Video